Manila, House Speaker Ferdinand Martin G. Romualdez announced significant progress in nuclear energy and healthcare following the signing of two US-Philippine’s agreements. These agreements mark a major step towards providing cheaper and cleaner energy, as well as enhancing cancer care in the Philippines.
According to Philippines News Agency, the first agreement between Meralco and Ultra Safe Nuclear Corporation (USNC) focuses on deploying Micro Modular Reactors (MMRs) in the Philippines. This initiative is seen as a game-changer in the country's energy sector, promising to deliver affordable, safe, and reliable nuclear energy. It aligns with President Ferdinand R. Marcos Jr.'s commitment to diversifying energy sources and addressing climate change challenges.
A feasibility study will be conducted under this agreement to explore the deployment of MMRs at Meralco sites. This study aims to assess the environmental and social impacts, along with the costs associated with constructing and operating MMR energy systems in the Philippines.
Romualdez also highlighted the upcoming signing of the 123 nuclear deal or the 'peaceful nuclear cooperation agreement' between the Philippines and the US government. This agreement, which will be signed on the sidelines of the APEC Summit in San Francisco, will enable civil nuclear energy cooperation and allow the export of nuclear technology and materials from the US to the Philippines.
In addition to the advancements in nuclear energy, Romualdez welcomed an agreement between Ayala Healthcare Holdings, Inc. and US-based Varian Medical Systems. This collaboration aims to improve access to quality cancer care in the Philippines by establishing the country's first dedicated specialty oncology hospital. The Healthway Cancer Care Hospital of AC Health will serve as the center of an oncology network throughout Metro Manila, ensuring comprehensive cancer care accessibility.
The agreement will also foster research and innovation in cancer diagnosis, treatment, and prevention. This is particularly significant considering that cancer has become the third leading cause of death in the Philippines, with approximately 141,021 new cancer cases and 86,337 deaths annually.
Lastly, Romualdez lauded a joint venture between Lloyd Laboratory and DIFGEN Pharmaceuticals for the development and export of a sterile solution to the United States. This partnership is aimed at positioning the Philippines as a key player in the global pharmaceutical exports market.